Inhaled drug CDMO Vectura has announced the appointments of Trevor Archbold, Robert Gurley, and Chris Vernall as Business Development Directors, reporting to recently appointed Chief Commercial Officer Mark Bridgewater. Archbold and Vernall will cover Europe; Gurley will be responsible for the US West Coast.
Archbold was most recently Strategic Account Manager, Pharma Solutions for DuPont Nutrition and Biosciences and previously held a number of roles at Dow Chemical, Croda, and Catalent. Gurley was most recently Director of Sales & Business Development at Cambrex and also previously worked in Business Development at Catalent, as well as EAG Laboratories and Cardinal Health.
Earlier this year, Nanopharm announced that Vernall had been appointed as its Director of Business Development after serving in that same role at Intertek Melbourn. He will begin his new role at Vectura in August.
Vectura announced in July 2019 that it would begin transitioning from developing its own inhaled drugs to a contract developer of OINDPs. In October 2019, the company appointed Will Downie as CEO in order to “help Vectura to grow and deliver on its new strategic focus as a leading inhaled CDMO business.” Earlier this year, Vectura appointed Sharon Johnson as Executive VP for Delivery Management.
Bridgewater commented, “As we continue with our growth, business strategy and focus on provider services to the industry, a strong and experienced business development team is vital. We welcome Trevor, Robert, and Chris to Vectura, and with the experience they bring, I am sure their skills will help with our mission to transform Vectura into a true leader in the outsourcing space.”
Read the Vectura press release.
